Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer-Reference-Cited by-同舟云学术

Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer

Published:2022-07-14 Issue:2 Volume:1 Page:119-123
ISSN:2770-9183
Container-title:Cancer Innovation
language:en
Short-container-title:Cancer Innovation

Author:

Guan Xiuwen¹,Ma Fei¹²^ORCID,Xu Binghe¹²

Affiliation:

1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cai2.21

Reference10 articles.

1. HER2-positive breast cancer

2. Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy

3. Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

4. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

5. Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023);Expert Opinion on Therapeutic Patents;2024-02

2. Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis;Frontiers in Endocrinology;2023-12-11

3. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now;Breast Cancer Research;2023-10-03

4. Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with HER2‐positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study;International Journal of Cancer;2023-08-06

5. Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer;Signal Transduction and Targeted Therapy;2023-03-19